ATE412433T1 - Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien - Google Patents

Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien

Info

Publication number
ATE412433T1
ATE412433T1 AT00910138T AT00910138T ATE412433T1 AT E412433 T1 ATE412433 T1 AT E412433T1 AT 00910138 T AT00910138 T AT 00910138T AT 00910138 T AT00910138 T AT 00910138T AT E412433 T1 ATE412433 T1 AT E412433T1
Authority
AT
Austria
Prior art keywords
treating tumors
cytokine
angiogenic
metastasis
methods
Prior art date
Application number
AT00910138T
Other languages
English (en)
Inventor
Holger Lode
Ralph Reisfeld
David Cheresh
Stephen Gillies
Original Assignee
Scripps Research Inst
Emd Serono Res Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Emd Serono Res Ct Inc filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE412433T1 publication Critical patent/ATE412433T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT00910138T 1999-02-12 2000-02-11 Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien ATE412433T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11972199P 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
ATE412433T1 true ATE412433T1 (de) 2008-11-15

Family

ID=22385967

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910138T ATE412433T1 (de) 1999-02-12 2000-02-11 Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien

Country Status (22)

Country Link
US (3) US7115261B1 (de)
EP (1) EP1156823B1 (de)
JP (2) JP4841727B2 (de)
KR (1) KR100704140B1 (de)
CN (1) CN1192796C (de)
AT (1) ATE412433T1 (de)
AU (1) AU776790B2 (de)
BR (1) BR0008161A (de)
CA (1) CA2360106C (de)
CZ (1) CZ303155B6 (de)
DE (1) DE60040651D1 (de)
DK (1) DK1156823T3 (de)
ES (1) ES2313883T3 (de)
HU (1) HU229520B1 (de)
MX (1) MXPA01008110A (de)
NO (2) NO331072B1 (de)
PL (1) PL200919B1 (de)
PT (1) PT1156823E (de)
RU (1) RU2236251C2 (de)
SI (1) SI1156823T1 (de)
SK (1) SK287357B6 (de)
WO (1) WO2000047228A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CA2460321A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Chemokines as adjuvants of immune response
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
CA2472578A1 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
GB0217017D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 2
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
EP1547609A1 (de) * 2002-09-04 2005-06-29 Proteinexpress Co., Ltd. Embryo-implantationsinhibitor
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7196061B2 (en) * 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
CN100342017C (zh) * 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
JPWO2006080171A1 (ja) 2005-01-31 2008-06-19 株式会社 エフェクター細胞研究所 免疫増強剤
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
NZ616992A (en) * 2005-12-20 2015-07-31 Sbi Biotech Co Ltd Anti-ilt7 antibody
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US20090220521A1 (en) * 2008-01-04 2009-09-03 Randolf Kerschbaumer Anti MIF Antibodies
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
NZ592943A (en) * 2008-11-17 2012-09-28 Uinv Kobenhavns Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
CN108181457B (zh) 2009-03-12 2021-03-30 癌症预防和治疗有限公司 鉴定、评估、预防以及治疗肺疾病的方法及试剂盒
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
ES2726946T3 (es) * 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2646468B1 (de) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf-zusammensetzungen und ihre verwendung
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
KR20130118941A (ko) * 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AU2012249288C1 (en) * 2011-04-29 2017-12-21 Lung Cancer Proteomics Llc Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
EP2537933A1 (de) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
CN103827143A (zh) 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
RU2014109038A (ru) 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
US9958456B2 (en) 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker
CN102634485A (zh) * 2012-03-15 2012-08-15 上海市浦东新区公利医院 一种表达il-17的胶质瘤细胞株
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
US11401312B2 (en) 2013-04-19 2022-08-02 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
AU2014309199B2 (en) * 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6827319B2 (ja) 2014-05-08 2021-02-10 中外製薬株式会社 Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016086044A1 (en) * 2014-11-24 2016-06-02 University Of Iowa Research Foundation Methods of treating cancer
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
CN106906184B (zh) * 2017-02-27 2021-04-23 广东昭泰体内生物医药科技有限公司 一种促进肺癌细胞生长的方法
MX2019011717A (es) 2017-03-31 2019-12-16 Univ California Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.
CN110709936A (zh) 2017-04-04 2020-01-17 肺癌蛋白质组学有限责任公司 用于早期肺癌预后的基于血浆的蛋白质概况分析
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CN111562362B (zh) * 2020-04-02 2022-05-20 臻悦生物科技江苏有限公司 一组用于预测三阴乳腺癌免疫联合抗血管生成治疗效果的标志物及其应用和试剂盒
CN111440244B (zh) * 2020-04-09 2021-03-16 诺未科技（北京）有限公司 靶向vegfr2的转移性癌疫苗
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262520A (en) 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
DE69133036T2 (de) * 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
PT910382E (pt) * 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
EP0951295B1 (de) 1996-05-31 2010-06-09 The Scripps Research Institute Zusammenstellungen zur verwendung als alpha-v-beta3 vermittelter angiogenesis hemmers

Also Published As

Publication number Publication date
US7365054B2 (en) 2008-04-29
MXPA01008110A (es) 2002-10-23
CZ303155B6 (cs) 2012-05-09
KR100704140B1 (ko) 2007-04-09
NO20013906L (no) 2001-10-09
PT1156823E (pt) 2009-01-08
ES2313883T3 (es) 2009-03-16
US20090060864A1 (en) 2009-03-05
CN1346279A (zh) 2002-04-24
DK1156823T3 (da) 2009-01-19
SK11132001A3 (sk) 2002-06-04
RU2236251C2 (ru) 2004-09-20
NO20101696L (no) 2001-10-09
US7833976B2 (en) 2010-11-16
WO2000047228A1 (en) 2000-08-17
US20070036751A1 (en) 2007-02-15
KR20010102043A (ko) 2001-11-15
DE60040651D1 (de) 2008-12-11
US7115261B1 (en) 2006-10-03
AU3228000A (en) 2000-08-29
JP2011207892A (ja) 2011-10-20
CZ20012791A3 (cs) 2002-05-15
PL350329A1 (en) 2002-12-02
CN1192796C (zh) 2005-03-16
JP2002536419A (ja) 2002-10-29
CA2360106A1 (en) 2000-08-17
JP4841727B2 (ja) 2011-12-21
PL200919B1 (pl) 2009-02-27
EP1156823A1 (de) 2001-11-28
SI1156823T1 (sl) 2009-02-28
CA2360106C (en) 2012-10-30
EP1156823A4 (de) 2003-02-19
AU776790B2 (en) 2004-09-23
BR0008161A (pt) 2002-05-28
NO20013906D0 (no) 2001-08-10
NO331072B1 (no) 2011-09-26
HU229520B1 (en) 2014-01-28
HUP0200128A2 (en) 2002-05-29
SK287357B6 (sk) 2010-08-09
EP1156823B1 (de) 2008-10-29

Similar Documents

Publication Publication Date Title
ATE412433T1 (de) Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
DK0784683T3 (da) TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
ATE215565T1 (de) Verwendung von anti-vegf antikörpern zur behandlung von krebs
DE69840723D1 (de) Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
DK0970126T3 (da) Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
DE69942274D1 (de) Methoden zur amyloidentfernung mit anti-amyloid-antikörper
TR200102423T2 (tr) Peptid ligandları yoluyla bağlı birden fazla imünojenik bileşeni olan HBV çekirdek antijeni parçacıkları
MA52630B1 (fr) Procédés de traitement de l'hémophilie a
DK0910407T3 (da) Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons
DK0388914T3 (da) Monoklonale antistoffer (MAK) mod tumorassocierede antigener, deres fremstilling og anvendelse
NO986088D0 (no) Polypeptider med evnen til Õ danne antigenbindende strukturer med spesifisi
DE69133242D1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
DE60238555D1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
Eger et al. Generation and characterization of a human/mouse chimeric GD2-mimicking anti-idiotype antibody ganglidiximab for active immunotherapy against neuroblastoma
GB0102145D0 (en) Substances
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
ATE364398T1 (de) Perylenequinone zur anwendung mit immunotherapeutischen mitteln
MX2021009500A (es) Anticuerpos anti-trem1 y metodos relacionados.
WO2001075109A3 (en) Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
ATE480250T1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
CY1113344T1 (el) Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1156823

Country of ref document: EP